lithium sodium 3-amino-10-{4-(10-amino-6,13-dichloro-4,11-disulfonatobenzo[5,6][1,4]oxazino[2,3-b]phenoxazine-3-ylamino)-6-[methyl(2-sulfonato-ethyl)amino]-1,3,5-triazin-2-ylamino}-6,13-dichlorobenzo[5,6][1,4]oxazino[2,3-b]phenoxazine-4,11-disulfonate

IDENTIFICATION NUMBERS

- **CAS:** 154212-58-5

CLASSIFICATION AND LABELLING (Regulation 1272/2008)

Symbols



GHS07

Acute toxicity (oral, dermal, inhalation



GHS08

Respiratory sensitisation

Signal word: **Danger**

H Phrases

H332 : Harmful if inhaled

Acute Tox. (Cat. 4 *) : Acute toxicity

H312 : Harmful in contact with skin

Acute Tox. (Cat. 4 *) : Acute toxicity

H302 : Harmful if swallowed

Acute Tox. (Cat. 4 *) : Acute toxicity

H371 : May cause damage to organs

STOT SE (Cat. 2 **) : Specific target organ toxicity - single exposure

Specific environmental risks

Atmospheric emissions

Substances subject to atmospheric emission limitations under the Industrial Emissions Directive (2010/75/EU) and its Spanish transposition. Includes pollutants regulated in industrial installation emission permits and best available technique reference documents (BAT/BREF).

Restriction/prohibition regulations

Substances under PACT evaluation

Substances under active regulatory monitoring through ECHA's PACT (Public Activities Coordination Tool). Allows tracking which regulatory authorities are examining a substance and what potential regulatory actions are being considered (restriction, SVHC identification, harmonised classification, etc.).